Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Clin Cancer Res. 2013 Apr 2;19(11):2984–2994. doi: 10.1158/1078-0432.CCR-12-2008

Figure 5.

Figure 5

A. Combination of both the antibodies effectively inhibits HUVEC tube formation in presence of ligands. HUVECs were grown Medium 200, then stimulated with VEGF in the absence of antibodies (PBS), or MEDI-573 (30 μg/ml) plus IGF-1 (10 ng/ml) or IGF-2 (50 ng/ml) or MEDI-573 with MAB391 and both IGF-1 and IGF-2. Tube formation was quantified as described in Materials and Methods. Each result is the mean ± SE for 3 independent experiments .B. Matrigel plugs containing with PBS, VEGF (100 ng/ml) or VEGF (100 ng/ml) plus IGF-2 (50 ng/ml) were implanted subcutaneously in mice. Mice received no treatment, MEDI-573 (30 mg/kg), CP1-B02 (C (20 mg/kg) or both antibodies on day 0 (after Matrigel plug implantation) and day 3. The Matrigel plugs were excised on day 7, and processed as described in the legend to Figure 3 (Mean ± SE from 6 high-power fields).